- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07944963
Sacral Erector Spinae Plane Block for Catheter-Related Bladder Discomfort After HoLEP
Evaluation of the Effect of Bilateral Sacral Erector Spinae Plane Block on Postoperative Catheter-Related Bladder Discomfort in Patients Undergoing Holmium Laser Enucleation of the Prostate
Catheter-related bladder discomfort (CRBD) is common after holmium laser enucleation of the prostate (HoLEP). This single-center, randomized, controlled, assessor-blinded trial evaluates whether an ultrasound-guided bilateral sacral erector spinae plane (S-ESP) block performed before general anesthesia reduces the incidence of CRBD compared with general anesthesia alone in men aged 50 to 80 years undergoing elective HoLEP. The primary outcome is the incidence of CRBD at 1 hour after surgery.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Catheter-related bladder discomfort (CRBD) is a common and distressing postoperative symptom complex in male patients undergoing Holmium Laser Enucleation of the Prostate (HoLEP), characterized by a suprapubic burning sensation, an urge to void, and involuntary bladder spasms due to three-way urinary catheterization and continuous bladder irrigation. The sacral erector spinae plane (S-ESP) block is an ultrasound-guided interfascial plane block that targets the S2-S4 sacral nerve roots, which provide both somatic (via the pudendal nerve) and visceral parasympathetic (via pelvic splanchnic nerves) innervation to the lower urinary tract. While current evidence regarding the efficacy of the S-ESP block against a no-block control group in HoLEP surgery is limited, blocking these sacral pathways may effectively modulate afferent bladder stimuli.
A total of 100 male patients aged 50 to 80 years with ASA physical status I-III scheduled for elective HoLEP surgery under general anesthesia will be randomly assigned in a 1:1 ratio to either the S-ESP block group (Group S, n=50) or the standard care control group (Group G, n=50) using computer-generated randomization and sealed opaque envelopes.
Patients in Group S will be placed in the prone position approximately 30 minutes before surgery under standard monitoring. Using a convex ultrasound transducer (GE HealthCare C1-5 probe) in a longitudinal paramedian orientation at the S2 intermediate sacral crest level, a 22G 80-100 mm echogenic block needle will be advanced in-plane in a craniocaudal direction into the fascial plane between the erector spinae aponeurosis and the sacral crest. Following hydrodissection with 1-2 mL normal saline and negative aspiration, 20 mL of 0.25% bupivacaine will be injected on each side (total 40 mL, 100 mg; not exceeding the maximum safe dose of 2 mg/kg). Sensory blockade will be assessed 30 minutes after block completion via pinprick testing over the bilateral S2-S4 dermatomes.
Both groups will receive a standardized general anesthesia protocol: induction with IV fentanyl (1 mcg/kg), propofol (2-2.5 mg/kg), and rocuronium (0.3 mg/kg) to facilitate laryngeal mask airway (LMA) insertion, followed by maintenance with 1 MAC sevoflurane and titrated remifentanil infusion (0.05-0.2 mcg/kg/min). Approximately 30 minutes before the end of surgery, all patients will receive IV paracetamol (1 g) and IV tramadol (100 mg) for multimodal analgesia, followed by routine postoperative IV paracetamol (1 g twice daily).
An independent anesthesiologist blinded to group allocation will assess postoperative outcomes at 30 minutes and at 1, 2, 4, 6, 12, and 24 hours. If the Visual Analog Scale (VAS) pain score is ≥4, IV tramadol (1 mg/kg, up to 400 mg/day) will be administered as rescue analgesia. If the CRBD score is ≥2 after excluding mechanical catheter obstruction, rescue antispasmodic or antimuscarinic medication will be administered. Quality of recovery will be evaluated at 24 hours using the validated Turkish version of the 15-item Quality of Recovery scale (QoR-15T).
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Kadriye Divrak, MD
- Numéro de téléphone: 00905453712155
- E-mail: kadriyedivrak@gmail.com
Sauvegarde des contacts de l'étude
- Nom: Derya Ozkan, Prof., MD
- Numéro de téléphone: 00905425843638
- E-mail: derya_z@yahoo.com
Lieux d'étude
-
-
-
Ankara, Turquie (Türkiye), 06170
- Ankara Etlik City Hospital
-
Contact:
- Kadriye Dıvrak, MD
- Numéro de téléphone: 00905453712155
- E-mail: kadriyedivrak@gmail.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Male patients aged between 50 and 80 years
- American Society of Anesthesiologists (ASA) physical status class I to III
- Scheduled for elective Holmium Laser Enucleation of the Prostate (HoLEP) surgery under general anesthesia
- Patients who agree to participate in the study and sign the written informed consent form
Exclusion Criteria:
- Age under 50 years or over 80 years
- ASA physical status class IV or higher
- Known hypersensitivity or allergy to local anesthetics
- History of chronic opioid use
- Chronic pain syndrome
- History of peripheral neuropathy, sacral neurological disease, or neurogenic bladder
- Overactive bladder or prominent preoperative bladder irritation symptoms
- History of previous prostate, bladder neck, or lower urinary tract surgery
- Active urinary tract infection
- Anticoagulant/antiplatelet use that contraindicates block administration according to current regional anesthesia guidelines, or clinically significant coagulopathy
- Infection or severe dermatological lesion at the block application site
- Severe renal failure (eGFR < 30 mL/min/1.73m2) or clinically significant hepatic failure
- Cognitive impairment, communication difficulty, or psychiatric/neurological condition preventing postoperative assessments
- Anticipated need for postoperative intensive care unit admission
- Presence of a preoperative indwelling urinary catheter
- Emergency surgery
- Patient refusal or withdrawal of consent
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: S-ESPB Group
Ultrasound-guided bilateral sacral erector spinae plane block with 20 mL of 0.25% bupivacaine per side, performed about 30 minutes before surgery, followed by standardized general anesthesia. |
Ultrasound-guided bilateral sacral erector spinae plane block with 20 mL of 0.25% bupivacaine per side, performed about 30 minutes before surgery, followed by standardized general anesthesia |
|
Comparateur actif: Standard Care Group
Standardized general anesthesia without any block or sham injection. |
Standardized general anesthesia without any block. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Incidence of Catheter-Related Bladder Discomfort (CRBD) at Postoperative 1 Hour
Délai: 1 hour after surgery
|
CRBD is graded on a 4-point scale: 0 = none; 1 = mild (reported only on questioning); 2 = moderate (reported spontaneously, without behavioral responses); 3 = severe (reported spontaneously with behavioral responses such as strong verbal response, flailing limbs or attempts to remove the catheter). Incidence is the proportion of patients with a score of 1 or higher. |
1 hour after surgery
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Incidence of CRBD at other time points
Délai: 30 minutes and 2, 4, 6, 12 and 24 hours after surgery
|
Proportion of patients with CRBD score of 1 or higher |
30 minutes and 2, 4, 6, 12 and 24 hours after surgery
|
|
Severity of CRBD
Délai: 30 minutes and 1, 2, 4, 6, 12 and 24 hours after surgery
|
CRBD severity will be graded on a 4-point ordinal scale from 0 (none) to 3 (severe). Moderate-to-severe CRBD is defined as a score ≥2. |
30 minutes and 1, 2, 4, 6, 12 and 24 hours after surgery
|
|
Postoperative pain score
Délai: 30 minutes and 1, 2, 4, 6, 12 and 24 hours after surgery
|
Postoperative pain intensity will be assessed using a 10-cm Visual Analog Scale (VAS) ranging from 0 (no pain) to 10 (worst pain). |
30 minutes and 1, 2, 4, 6, 12 and 24 hours after surgery
|
|
Intraoperative remifentanil consumption
Délai: Intraoperative period
|
Total amount of intraoperative remifentanil consumed, recorded in micrograms (mcg) and normalized to body weight and duration (mcg/kg/hour). |
Intraoperative period
|
|
Total Postoperative Rescue Analgesic Consumption
Délai: First 24 hours after surgery
|
Total intravenous tramadol dose in milligrams |
First 24 hours after surgery
|
|
Time to First Rescue Analgesic Request
Délai: First 24 hours after surgery
|
Minutes from end of surgery to first rescue tramadol dose |
First 24 hours after surgery
|
|
Antispasmodic or antimuscarinic requirement
Délai: First 24 hours after surgery
|
Proportion of patients requiring additional antispasmodic or antimuscarinic medication for persistent moderate-to-severe CRBD (score ≥2) |
First 24 hours after surgery
|
|
Incidence of Postoperative Nausea and Vomiting (PONV) and Other Adverse Events
Délai: First 24 hours after surgery
|
Number and percentage of participants experiencing postoperative nausea and vomiting (PONV) or any block- or anesthesia-related adverse events. |
First 24 hours after surgery
|
|
Postoperative Quality of Recovery Score (QoR-15T)
Délai: At 24 hours after surgery
|
Quality of recovery will be evaluated using the validated Turkish version of the 15-item Quality of Recovery scale (QoR-15T). Total scores range from 0 to 150, with higher scores indicating better postoperative recovery quality. |
At 24 hours after surgery
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Derya Ozkan, Prof., MD, Ankara Etlik City Hospital
Publications et liens utiles
Publications générales
- Wang SY, Qiu Q, Shen X. Effect of Pudendal Nerve Block on the Prevention of Postoperative Bladder Spasm and Catheter-Related Bladder Discomfort in Male Patients Undergoing Transurethral Holmium Laser Enucleation of the Prostate. Clin Interv Aging. 2022 Nov 30;17:1729-1738. doi: 10.2147/CIA.S384612. eCollection 2022.
- Dost B, Narayanan M, Marrone F, De Cassai A, Tulgar S, Aksu C, Merjavy P, Chin KJ. The Sacral Erector Spinae Plane Block: A Narrative Review. Pain Ther. 2026 Feb;15(1):131-147. doi: 10.1007/s40122-025-00807-6. Epub 2025 Dec 23.
- Rinaldi P, Garo ML. Efficacy and safety of sacral erector spinae plane (S-ESP) block in adult and pediatric patients during surgical procedures: A comprehensive systematic review and meta-analysis. J Clin Anesth. 2026 Apr;111:112181. doi: 10.1016/j.jclinane.2026.112181. Epub 2026 Mar 11.
- Akkaya T, Ozkan D, Karakoyunlu N, Ergil J, Gumus H, Ersoy H, Comert A, Acar HI, Yildiz S. Pudendal block in transurethral prostatectomy: A randomised trial. Eur J Anaesthesiol. 2015 Sep;32(9):656-7. doi: 10.1097/EJA.0000000000000172. No abstract available.
- Olgun Keles B, Tekir Yilmaz E, Altinbas A. Comparison between the Efficacy of Sacral Erector Spina Plane Block and Pudendal Block on Catheter-Related Bladder Discomfort: A Prospective Randomized Study. J Clin Med. 2024 Jun 20;13(12):3617. doi: 10.3390/jcm13123617.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies urogénitales
- Maladies génitales
- La douleur
- Manifestations neurologiques
- Complications postopératoires
- Processus pathologiques
- Maladies génitales, sexe masculin
- Maladies de la prostate
- Maladies urogénitales masculines
- Conditions pathologiques, signes et symptômes
- Signes et symptômes
- Douleur, Postopératoire
- Hyperplasie prostatique
Autres numéros d'identification d'étude
- AEŞH-EK-2026-180
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
All personal data will be anonymized and individual participant data will not be made publicly available in accordance with institutional ethics committee approval.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .